CD274 and non-small cell lung carcinoma: In contrast, in the setting of chemo-immunotherapy combinations in NSCLC, clinical trial analyses have shown that pembrolizumab provides comparable progression-free survival benefits regardless of PD-L1 expression levels (≥1% vs. <1%) [21].